Onco Actu du 25 novembre 2019

	3.1.1 PRÉVENTION - TABAC - E-CIGS
Massive Irony: American Heart Association is Lying to the Public in a Campaign Attacking E-Cigarette Companies for Lying [The Rest of the Story] In a massive ironic twist, it is actually the American Heart Association that is lying, and their lies -- unlike anything that e-cigarette companies have asserted -- are actually leading more people to smoking and possibly landing some vapers in hospitals.
Trump Warns a Flavor Ban Would Spawn Counterfeit Vaping Products [NY Times] The president again questioned the need for restrictions on e-cigarettes aimed at curbing use among teenagers, who tend to favor fruit and mint flavors.
How Juul Hooked a Generation on Nicotine [NY Times] The company planted the seeds of a public health crisis by marketing to millennials, who had low smoking rates, and it ignored evidence that teenagers were using its products.
Trump says ban of some flavored e-cigarette products could lead to illegal sales [Reuters] On Friday, Trump, who is gearing up for a 2020 re-election race and trumpets the strength of the U.S. economy daily, was warned by an e-cigarette executive that a ban on the products could lead to a loss of at least 100,000 jobs.
	3.3 PRÉVENTION - VACCINS
New Cochrane Review assesses different HPV vaccines and vaccine schedules in adolescent girls and boys [Wiley] New evidence published in the Cochrane Library today provides further information on the benefits and harms of different human papillomavirus (HPV) vaccines and vaccine schedules in young women and men.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Commercial Prognostic Tests for Prostate Cancer May Not Be Accurate in African American Men [AACR] “Until the risk prediction accuracy of the tests has been thoroughly studied in African American patients, we urge caution in their use for clinical decision-making. We hope that our report escalates interest in validating the utility of genomic risk predictors in African American men.”
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Consumer DNA Testing May Be the Biggest Health Scam of the Decade [Gizmodo] Given how popular at-home DNA testing has become, there’s really no sealing the genie back in the bottle. So if you want to get your genetic horoscope read this holiday, don’t let me stop you. But it’s a big decision you should sleep on. After all, once your DNA is out there, there’s no going back.
	5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS
Using Artificial Intelligence to determine whether immunotherapy is working [Case Western Reserve University] Prasanna said the initial study used CT scans from 50 patients to train the computer and create a mathematical algorithm to identify the changes in the lesion. He said the next step will be to test the program on cases obtained from other sites and across different immunotherapy agents.
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer [Institute of Cancer Research] Crucially, the researchers showed it was possible to predict in advance who was more likely to benefit from pembrolizumab by testing for the PD-L1 immune marker in tumours and on surrounding cells – a key step in establishing the drug’s use as a new standard of care.
	5.16 TRAITEMENTS - CHIRURGIE
Early removal of slow-growing brain tumours dramatically improves survival [University College London] A shift in surgical practice over the last decade towards the earlier removal of a type of slow-growing but ultimately fatal brain tumour has led to dramatic improvements in survival and seizure control for patients, a study at UCLH and UCL has found.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
Calquence OK boosts AstraZeneca's challenge to Imbruvica [Biopharma Dive] AstraZeneca said Calquence's sales of $108 million were aided by pre-approval use in CLL. Thanks to the new approval, Berens forecasts annual sales growth of 29% through 2030, which would make it a blockbuster by 2023.
EMA Recommends Extension of Indications for Lenalidomide [ESMO] New indication concerns combination therapy with rituximab for previously treated follicular lymphoma.
AstraZeneca scores again: Calquence approved for CLL as BTK race heats up [EndPoints] Calquence is part of the next generation of BTK inhibitors that have promised to be safer and more tolerable to patients.
AstraZeneca shares rise on early U.S. approval for leukemia drug [Reuters] Astra shares have risen 28% this year, boosted by revenue growth from new drugs.
	5.4 TRAITEMENTS - ECONOMIE
Teva to Resume Production of Critical Pediatric Oncology Drug: Too Little, Too Late [Bill of Health] Teva’s decision seems like “too little, too late” for having an appreciable effect on the current shortage that we are facing. For one, Pfizer is expected to be able to resume shipments this month. Second, Teva’s production will not be available until early 2020, which is when Pfizer asserts that they will be able to return to normal production levels of vincristine by.
	5.6.17 ESMO - FOIE
Atezolizumab in Combination with Bevacizumab Provides Superior Outcome Compared with Sorafenib in Unresectable HCC [ESMO] IMbrave150 results may be practice changing in the first-line setting for unresectable hepatocelluar carcinoma.
Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer [Roche] First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival in people with unresectable hepatocellular carcinoma compared with sorafenib.
Roche says Tecentriq cocktail helps liver cancer patients live longer [Reuters] Liver cancer is common in China, Roche’s No. 2 market after the United States and an engine of the Basel-based company’s growth.
	5.6.4 ESMO - POUMON
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori [Fierce Pharma] Overall, Alunbrig stalled tumor progression by 29.4 months, versus 9.2 months with Xalkori, as assessed by investigators. When it comes to the independent review committee, which is usually preferred by the FDA, median PFS was 24.0 months for Alunbrig and 11.0 months for the Pfizer drug.
Takeda announces positive new ALK+ lung cancer data as list of crizotinib successors widens [EndPoints] The trial compared the drug, Alunbrig (brigatinib), against an early inhibitor that is no longer best-in-class and the Japanese pharma will likely face significant competition if regulators grant an expanded label.
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up [Takeda] Median Progression-Free Survival with ALUNBRIG was Three Times Longer than that with Crizotinib.
Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib [Reuters] The company hopes to get U.S. regulatory approval for Alunbrig as a frontline drug for lung cancer in the fiscal year ending March 2021.
	5.6.6 ESMO - SEIN
First China-manufactured Trastuzumab Biosimilar HLX02 Global Phase III Trial Met Primary Endpoint in Breast Cancer [ESMO] The new study randomised women with HER2-positive breast cancer to HLX02, a fully humanised anti-HER2 that was developed in China as a trastuzumab biosimilar, or to reference trastuzumab sourced from the European Union.
	6. LUTTE CONTRE LES CANCERS
A Cancer Care Approach Tailored To The Elderly May Have Better Results [NPR] Though geriatric assessments were developed about two decades ago and hailed as one of the clinical cancer advances of 2012 by the American Society of Clinical Oncology, they are still not widely used by oncologists.
Oncologist Azra Raza: ‘Don’t give up hope. Don’t give in to despair’ [The Guardian] The Columbia professor on taking healthcare out of the stone age, her ideas for cancer prevention – and why getting too close to patients is an occupational hazard.
	6.1 OBSERVATION
Unique Factors Impact Outcome in AYA Patients with Cancer [ESMO] Characteristics of cancer in adolescents and young adults are defined and suggestions provided to improve survival.
Cancer: One in five cancer diagnoses 'in Emergency Departments' [BBC News] One in five people in Northern Ireland receive their cancer diagnosis while attending an emergency department (ED), according to research by the NI Cancer Registry.
Cancer patients have an up to ten times increased risk of dying of heart disease, major research shows [The Telegraph] The research, published in the European Heart Journal, compared the US population with more than 3.2 million cancer survivors.
	6.10.1 POLITIQUES (USA)
Trump says he will allow states to import prescription drugs to lower costs [Reuters] Drug companies have staunchly opposed such a plan, which has been mulled for years but never implemented.
	6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
Toni Bark has cancer [Respectful Insolence] I want to discuss the part of the video around the 4:50 mark, where the interviewer asks Bark to address the questions that “they” had “poisoned you.” (Apparently, unsurprisingly, Toni Bark’s fans think that the only way she could have gotten cancer is because someone “poisoned” her.)